Lisdexamfetamine Dimesylate: In Attention-Deficit Hyperactivity Disorder in Adults

• Published in: CNS drugs 2009-01, Vol.23 (5), p.419-425
• Main Authors: Weber, Juliane, Siddiqui, M. Asif A.
• Format: Article
• Language: English
• Subjects: Adis Drug Profile; Adult; Adults; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit disorders. Hyperactivity; Attention-deficit hyperactivity disorder; Biological and medical sciences; Central Nervous System Stimulants - pharmacology; Central Nervous System Stimulants - therapeutic use; Child; Child clinical studies; Clinical Trials, Phase III as Topic; Comorbidity; Complications and side effects; Dextroamphetamine; Dextroamphetamine - pharmacology; Dextroamphetamine - therapeutic use; Dopamine; Dosage and administration; Dose-Response Relationship, Drug; Drug dosages; Drug Evaluation; Drug therapy; Female; Humans; Hyperactivity; Lisdexamfetamine Dimesylate; Male; Medical sciences; Medicine; Medicine & Public Health; Neurology; Neuropharmacology; Neurosciences; Patient outcomes; Pharmacodynamics; Pharmacokinetics; Pharmacology. Drug treatments; Pharmacotherapy; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Questionnaires; Surveys and Questionnaires; Young Adult
• ISSN: 1172-7047; 1179-1934
• DOI: 10.2165/00023210-200923050-00005

▴ Lisdexamfetamine dimesylate is a long-acting amfetamine prodrug that requires in vivo hydrolysis to gradually release active d -amfetamine. It is approved in the US for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and in children aged 6—12 years. ▴ In a study in adult stimulant abusers, oral lisdexamfetamine 50 or 100 mg showed less ‘likability’ response than immediate-release d -amfetamine 40 mg on the Drug Rating Questionnaire-Subject (DRQS) Liking scale. However, there was no significant difference between lisdexamfetamine 150 mg and d -amfetamine 40 mg. ▴ In a randomized, double-blind, phase III trial in adult patients with ADHD, oral lisdexamfetamine 30, 50 or 70mg/day for 4 weeks caused a significantly greater improvement in ADHD-Rating Scale (ADHD-RS) total score than placebo; significant between-group differences favouring lisdexamfetamine were evident after 1 week. ▴ Lisdexamfetamine was generally well tolerated in adult patients with ADHD, with most treatment-emergent adverse events being of mild to moderate severity and consistent with the known effects of psychostimulants.